论文部分内容阅读
目的探讨伴代谢综合征(MS)的精神分裂症患者认知功能损害特点,为MS的早期干预提供理论依据。方法选取符合入组标准的精神分裂症患者268例做为研究对象,伴MS组64例,不伴MS组(非MS组)204例。收集两组患者一般资料,检测空腹血糖(FPG)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)等代谢指标,采用精神分裂症认知功能成套测验中文版(MCCB)评估认知功能,阳性和阴性症状量表(PANSS)评定临床症状。应用SPSS 18.0对数据进行统计分析,计数资料的比较用χ~2检验,计量资料的比较用独立样本t检验。结果 MS组与非MS组比较,体质指数(BMI)、腰围、FPG、TG、HDL-C、收缩压(SBP)和舒张压(DBP)差异均有统计学意义(P<0.05)。两组PANSS总分及各因子评分差异均无统计学意义(P>0.05)。与非MS组相比,MS组在处理速度、工作记忆、注意或警觉、言语学习记忆、视觉学习记忆维度评分差异均有统计学意义(P<0.05),而推理及问题解决、社会认知评分差异均无统计学意义(P>0.05)。结论伴发MS的精神分裂症患者认知功能损害较不伴MS精神分裂症患者更严重,在精神分裂症患者的临床治疗过程中早期识别与干预MS尤为重要。
Objective To investigate the characteristics of cognitive impairment in patients with schizophrenia with metabolic syndrome (MS) and provide a theoretical basis for early intervention of MS. Methods A total of 268 schizophrenic patients who met the inclusion criteria were selected as study subjects, 64 with MS, and 204 without MS (non-MS). The general data of two groups were collected and the metabolic indexes such as fasting blood glucose (FPG), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) were measured and assessed using the Chinese version of the cognitive function test for schizophrenia (MCCB) Cognitive function, positive and negative symptom scales (PANSS) were used to assess clinical symptoms. Statistical analysis was performed using SPSS 18.0. The comparison of count data was performed using χ ~ 2 test. The comparison of measurement data was performed with independent sample t-test. Results There were significant differences in body mass index (BMI), waist circumference, FPG, TG, HDL-C, SBP and DBP between MS group and non-MS group (P <0.05). There was no significant difference between the two groups in PANSS score and each factor score (P> 0.05). Compared with non-MS group, MS group had significant differences in processing speed, working memory, attention or alertness, verbal learning memory and visual learning memory dimension score (P <0.05), while reasoning and problem solving, social cognition There was no significant difference between the scores (P> 0.05). Conclusion Patients with schizophrenia with MS have more severe cognitive impairment than those without schizophrenia. Early identification and intervention of MS are particularly important in the clinical treatment of schizophrenia patients.